EPO and chronic kidney disease: FGF23 is known to be markedly elevated in late‐stage CKD, and it was demonstrated that normalization of iron utilization in mice with CKD via increasing EPO directly or indirectly resulted in lowered FGF23 (Noonan et al., 2020, 2021).